Loading...
DCVax®-L—Developed by Northwest Biotherapeutics
Dendritic cell (DC) immunotherapy is emerging as a potential addition to the standard of care in the treatment of glioblastoma multiforme (GBM). In the last decade or so various research groups have conducted phase I and II trials of DC-immunotherapy on patients with newly diagnosed (ND) and recurre...
Na minha lista:
| Udgivet i: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4514134/ https://ncbi.nlm.nih.gov/pubmed/25483653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29276 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|